Cell Therapeutics (CTIC) falls on settlement
Normal 0 false false false MicrosoftInternetExplorer4 Cell Therapeutics Inc (NASDAQ: CTIC) shares dipped 1.3% to $1.55. The company, on Jan. 18, said it will pay $19 million and adopt new corporate governance measures under a settlement that ends nearly three years of litigation with shareholders. The shareholder lawsuit had accused the Seattle-based biotech of not accurately disclosing information about Pixantrone, the company’s drug for non-Hodgkin lymphoma. Share volume was 86,000, compared to an all-day average of 339,000 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here